Blood thinner xarelto cuts amputation risk by 70%

Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease (PAD) and also a 23 percent reduction in deaths in patients with coronary artery disease (CAD).
Findings from the PAD analysis showed that Xarelto (rivaroxaban) 2.5mg twice daily, plus aspirin 100mg once daily substantially reduced the risk of major amputation by 70 percent and the risk of experiencing major adverse cardiovascular events (MACE), major adverse limb events (MALE) and major amputation by 31 percent compared with aspirin 100mg once daily alone.

David G. Armstrong

Dedicated to amputation prevention, wound healing, diabetic foot, biotechnology and the intersection between medical devices and consumer electronics.

Leave a Reply

%d bloggers like this: